PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) ECOG Performance Status of 0-1 within 28 days prior to registration. 2) Patients must have undergone complete surgical resection of their stage I (tumors = 4cm), IIA, IIB, and select IIIA (T3N1-2, T4N0-2) NSCLC according to the AJCC 8th edition with negative margins (R0). 3) Squamous or non-squamous NSCLC histology. 4) Surgery for this lung cancer must be completed < 60 days prior to starting treatment.

You may not be eligible for this study if the following are true:

  • 1) Tumors that have any component of small cell or large cell neuroendocrine histology are NOT eligible. 2) Tumors that are known to harbor EGFR mutations or ALK re-arrangements are NOT eligible. 3) Prior chemotherapy, radiation therapy, or immunotherapy is NOT allowed for the treatment of this lung cancer. 4) Prior chemotherapy and/or radiation therapy is permissible for the treatment of other previous cancers, but must have been completed at least 3 months prior to registration for this trial.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.